Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.

Benzinga

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

StockNews.com

Commentary: Overhyped Alzheimer’s treatments betrayed patients’ hopes. Here’s how science should change

America’s science policies are changing. America’s scientists need to change with them. The recent controversies over the Food and Drug Administration’s accelerated approval of an Alzheimer’s treatment are a lesson in the costs of failing to do so.

Los Angeles Times

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Benzinga

Why the world's still waiting for a dementia cure, and what we can do in the meantime

Many researchers agree that Alzheimer's disease actually starts decades before thinking and memory start to decline. What can we do about it?

ABC News

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of $30.05 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biden HHS hands a "gift to McConnell"

Latest HHS move should alarm "every Congressional Democrat who wants to keep their seat in November"

Salon

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of $29.43 billion.

Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Benzinga

Looking Into Biogen's Return On Capital Employed

According to Benzinga Pro, during Q1, Biogen (NASDAQ:BIIB) earned $218.50 million, a 1165.85% increase from the preceding quarter. Biogen's sales decreased to $2.53 billion, a 7.39% change since Q4.

Benzinga

Read Why Biogen Shares Are Trading Higher After Q1 Earnings

Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%. Spinraza's revenue of $441 million decreased 9% at actual currency and 6% at constant currency. Aduhelm's revenue was…

Benzinga

Recap: Biogen Q1 Earnings

Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Change at the top at Biogen after struggles with Aduhelm

Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining…

Benzinga

Earnings Preview For Biogen

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an earnings per share (EPS) of $4.38.

Benzinga

Analyst Ratings for Biogen

Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know

Biogen (NASDAQ:BIIB) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why This Analyst Believes Biogen Is 'Too Good to Ignore'

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022

Upgrades

The Conversation

The FDA approved a new drug to treat Alzheimer's, but Medicare won't always pay for it – a doctor explains what researchers know about Biogen's Aduhelm

Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.

Tribune News Service

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Tribune News Service

Commentary: Medicare is cleaning up the FDA’s mess on Biogen’s Alzheimer’s drug

Medicare has decided once and for all not to pay for Biogen’s new Alzheimer’s drug Aduhelm unless patients are enrolled in a clinical study.

Benzinga

Morning Brief: Top Stories Dominating Financial Media on Friday, April 8

Reuters

Benzinga

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.